Low-Dose Naltrexone Does Not Reduce Thyroid Function Tests in Hashimoto's Patients
The premise of your question is not supported by evidence—low-dose naltrexone (LDN) does not actually reduce thyroid hormone requirements or "drop thyroid numbers" in Hashimoto's patients, including those with Ehlers-Danlos syndrome (EDS). The largest and most rigorous study examining this question found no association between starting LDN and subsequent changes in thyroid hormone dispensing 1.
What the Evidence Actually Shows
Direct Evidence on LDN and Thyroid Function
A 2020 quasi-experimental study of 898 patients with hypothyroidism examined thyroid hormone consumption before and after starting LDN. The results showed no reduction in levothyroxine (LT4) or triiodothyronine (T3) requirements after initiating LDN—in fact, there was a tendency toward increasing LT4 consumption with greater LDN exposure 1. This directly contradicts claims that LDN reduces thyroid medication needs.
An older 2001 study in former opioid addicts on standard-dose naltrexone (50 mg daily, not low-dose) showed all subjects remained euthyroid, with some suggestion that longer naltrexone duration correlated with higher T3 levels—the opposite of what you're describing 2.
The Reality of LDN Evidence
Current evidence does not support routine clinical use of LDN for any indication, including autoimmune thyroid disease 3. A comprehensive 2026 narrative review found that early positive findings from uncontrolled studies were rarely replicated in placebo-controlled trials, and most available evidence consists of case reports and small feasibility studies prone to publication bias 3.
Why You May Be Seeing Apparent Improvements
Possible Explanations for Your Clinical Observations:
Natural disease fluctuation: Hashimoto's thyroiditis has a dynamic, fluctuating course. Studies show that 9% of patients with overt hypothyroidism can become euthyroid over time without intervention, and thyroid autoantibody levels naturally decrease significantly over 3-5 years 4.
Placebo effect and subjective outcomes: LDN studies rely heavily on subjective patient-reported outcomes. The drug is generally safe and well-tolerated at 4.5 mg daily 3, which may enhance placebo responses.
Regression to the mean: Patients often start treatments when symptoms are at their worst, and natural improvement may be attributed to the intervention.
Concurrent management changes: Thyroid hormone absorption can be affected by numerous factors including timing of administration, dietary changes, and other medications 5.
The EDS Connection
The 2025 AGA guideline on hypermobile EDS (hEDS) notes associations with autoimmune dysfunction and possible autoimmune etiologies for gastrointestinal symptoms 6. However, there is no established mechanism or evidence linking LDN to improved thyroid function specifically in EDS patients with Hashimoto's.
Key Caveats:
- Standard-dose naltrexone (50-300 mg) can cause hepatocellular injury 7, though LDN uses much lower doses (typically 4.5 mg)
- The FDA-approved naltrexone label does not mention thyroid effects as a recognized adverse event or therapeutic benefit 7
- Thyroid hormone requirements naturally decrease with age and weight loss 5
Clinical Bottom Line
If you're observing apparent improvements in thyroid function tests after starting LDN in your Hashimoto's/EDS patients, this is most likely due to the natural fluctuating course of autoimmune thyroiditis, placebo effects, or other concurrent factors—not a pharmacologic effect of LDN on thyroid function. Continue monitoring thyroid function every 4-8 weeks when making any changes 5, but don't attribute improvements to LDN based on current evidence. The drug may have a pragmatic role in treatment-resistant cases where standard therapies have failed, but its experimental status and uncertain efficacy must be clearly explained to patients 3.